© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
September 15, 2022
Triplet combination demonstrates a reduction in the risk of disease progression or death in individuals with previously untreated advanced intermediate- or poor-risk renal cell carcinoma.
September 14, 2022
Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation.
New research presented at ESMO Congress found that certain patients with advanced melanoma administered a combination of cemiplimab with fianlimab experienced a median progression-free survival of 2 years.
Researchers at the European Society for Medical Oncology Congress presented findings that show osimertinib may clinically reduce the risk of lung cancer recurrence.
September 13, 2022
Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.
An estimated 31.4% of individuals with non-squamous non–small cell lung cancer treated with the combination were alive at 3 years compared to 17.3% for those on chemotherapy alone.
Results demonstrated a 64.5% confirmed objective response rate in patients treated with the investigational combination.
Ribociclib with endocrine therapy was found to increase the median overall survival of patients with HR+/HER2- advanced breast cancer with visceral metastases to nearly 5 years.
Data presented at the 2022 ESMO congress show poziotinib has high activity in both treatment-naïve and previously treated patients with non-small cell lung cancer.
September 12, 2022
New results presented at the 2022 ESMO conference reinforce the potential of rucaparib as a first-line maintenance treatment option in a broad population of patients with ovarian cancer.